Amit Mahipal, MD, University Hospitals Seidman Cancer Center, and Richard S. Finn, MD, University of California, Los Angeles, discuss a recent study on real-world outcomes for patients with advanced hepatocellular carcinoma receiving lenvatinib following immunotherapy.
Advertisement
Ruxolitinib outperformed best available therapies in achieving durable hematocrit control in patients with polycythemia vera.
Ruxolitinib plus navitoclax induced 24-week spleen volume reduction rates twice as high as ruxolitinib plus placebo in MF.
Pelabresib plus ruxolitinib induced significant spleen volume reduction rates without limiting toxicities in myelofibrosis.
Over half of patients with low-risk myelofibrosis have evidence of disease progression.
A retrospective cohort study examined the prevalence and reasons for an unsatisfactory FIT, a common CRC screening modality.
The risk of CV-related mortality risk in patients with primary MF has not increased following the approval of ruxolitinib.
A study aimed to create a benefit-versus-harm shared decision-making tool for hydroxychloroquine for patients with SLE.
Megakaryocytes derived PF4 play an important role in the progression of myelofibrosis.
DocWire Content Partners
Gain insights from The CardioNerds, a group of cardiology experts who aim to democratize cardiovascular education.
Fundamentals, core concepts, and important management approaches in the field of hematology and oncology
Dr. Chadi Nabhan, a renowned voice in hematology and oncology, tackles a multitude of relevant health care topics.
Drs. Rohit Gosain and Rahul Gosain discuss practice-changing data and standards of oncology care.
Dr. Hady Lichaa is an interventional cardiologist specializing in complex coronary interventions.
Review important issues in the rheumatology space, including lupus, rheumatoid arthritis, and more, from Dr. Maheswaranathan.
Powered by DocWire News
The Latest From GI Oncology Now
A retrospective cohort study examined the prevalence and reasons for an unsatisfactory FIT, a common CRC screening modality.
Findings from the EDGE-Gastric trial suggest potential for 2 novel agents in patients with gastroesophageal adenocarcinoma.
According to a recent study, DAAs remain underutilized in patients with HCV-related HCC, despite improved survival outcomes.
Patients without microscopic vascular invasion had a better prognosis, and tumor number was found to be associated with pCR.
Investigators determined that progression-free survival for patients who received TACE plus camrelizumab was 6.2 months.
Investigators also researched the possibility that AI could predict progression-free survival.
The Latest From Heme Today
Ruxolitinib outperformed best available therapies in achieving durable hematocrit control in patients with polycythemia vera.
Ruxolitinib plus navitoclax induced 24-week spleen volume reduction rates twice as high as ruxolitinib plus placebo in MF.
Pelabresib plus ruxolitinib induced significant spleen volume reduction rates without limiting toxicities in myelofibrosis.
Pozelimab plus cemdisiran achieved intravascular hemolysis control in patients with paroxysmal nocturnal hemoglobinuria.
The FDA has accepted the BLA for crovalimab, an investigational treatment for paroxysmal nocturnal hemoglobinuria.
Tranexamic acid did not seem to increase risk of postoperative complications in patients undergoing total joint arthroplasty.
